EFL

Role: Mentor

Tracks: Life Sciences

Sapna Srivastava

Director, Independent

Dr. Srivastava has almost 25 years of experience in the biotechnology industry, encompassing independent director and senior executive roles in the biopharmaceutical companies, and as a senior biotechnology analyst on Wall Street. Her operational experience, as a Chief Financial and Strategy Officer, was focused on helping build companies with innovative technologies. Most recently, she served as the interim Chief Financial Officer for eGenesis, where she helped the company develop their financing strategy. Prior to which, she was at Abide Therapeutics (acquired by Lundbeck). Prior to Abide, she was at Intellia Therapeutics, where she played an integral role in leading the company’s strategy, financial operations and equity financings including initial public offering. Previously, Dr. Srivastava spent nearly 15 years as a biotechnology analyst on leading Wall Street firms. She was a senior biotechnology analyst at Goldman Sachs covering the large-cap companies, Morgan Stanley covering small to mid-cap companies, and ThinkEquity Partners, LLC. She began her career as a research associate at JP Morgan. Dr. Srivastava currently serves on the board of directors for multiple public and private companies. Public companies include Nuvalent Inc. (NUVL), Tourmaline Bio (TRML), Aura BioSciences (AURA), Innoviva (INVA) and Alumis, Inc (ALMS); Private companies include Asclepix Therapeutics and Velos Bio (acquired by Merck). She has also served as an advisor for Mergers and Acquisitions for select biotechnology companies either through her Board roles or as an independent advisor to transaction committees. Dr. Srivastava holds a Ph.D. from N.Y.U. University School of Medicine in Neuroscience, and a B.S. from St. Xavier’s College, University of Bombay.